You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

787 Results
Document
Oct 2021
Document
Oct 2021
Document
Oct 2021
Document
Oct 2021
Document
Oct 2021
Document
Oct 2021
Document
Oct 2021
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant
Funding:
Exceptional Access Program
    olaparib - For the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated, human epidermal growth factor receptor 2-negative high risk early breast cancer, based on criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
olaparib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Dec 2024
Document
Nov 2021
Document
Nov 2021
Drug
Other Name(s): Mylotarg®
Quick Link(s): Drug Monograph, Patient Info Sheet
Jun 2022
Document
Dec 2021

Pages